Correlation Between AN2 Therapeutics and Acrivon Therapeutics,

Can any of the company-specific risk be diversified away by investing in both AN2 Therapeutics and Acrivon Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining AN2 Therapeutics and Acrivon Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between AN2 Therapeutics and Acrivon Therapeutics, Common, you can compare the effects of market volatilities on AN2 Therapeutics and Acrivon Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in AN2 Therapeutics with a short position of Acrivon Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of AN2 Therapeutics and Acrivon Therapeutics,.

Diversification Opportunities for AN2 Therapeutics and Acrivon Therapeutics,

-0.05

Correlation Coefficient

AN2 Therapeutics  Acrivon Therapeutics,

Good diversification

The 3 months correlation between AN2 and Acrivon is -0.05. Overlapping area represents the amount of risk that can be diversified away by holding AN2 Therapeutics and Acrivon Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acrivon Therapeutics, and AN2 Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on AN2 Therapeutics are associated (or correlated) with Acrivon Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acrivon Therapeutics, has no effect on the direction of AN2 Therapeutics i.e., AN2 Therapeutics and Acrivon Therapeutics, go up and down completely randomly.

Pair Corralation between AN2 Therapeutics and Acrivon Therapeutics,

Given the investment horizon of 90 days AN2 Therapeutics is expected to under-perform the Acrivon Therapeutics,. In addition to that, AN2 Therapeutics is 1.82 times more volatile than Acrivon Therapeutics, Common. It trades about -0.12 of its total potential returns per unit of risk. Acrivon Therapeutics, Common is currently generating about 0.04 per unit of volatility. If you would invest  733.00  in Acrivon Therapeutics, Common on July 19, 2024 and sell it today you would earn a total of  42.00  from holding Acrivon Therapeutics, Common or generate 5.73% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

AN2 Therapeutics  vs.  Acrivon Therapeutics, Common

AN2 Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days AN2 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in November 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Acrivon Therapeutics,

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Acrivon Therapeutics, Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Acrivon Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in November 2024.

Pair Trading with AN2 Therapeutics and Acrivon Therapeutics,

The main advantage of trading using opposite AN2 Therapeutics and Acrivon Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if AN2 Therapeutics position performs unexpectedly, Acrivon Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics, will offset losses from the drop in Acrivon Therapeutics,'s long position.

The idea behind AN2 Therapeutics and Acrivon Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.